NHD Global
Growth Hormone & IGF · Modified GRF(1-29) research
Scientific Product Dossier
“CJC-1295 without DAC” is used commercially for a non-albumin-binding modified GRF(1-29)-type peptide. The classic CJC-1295 human trials studied the DAC form, so their 5.8–8.1 day half-life and prolonged exposure cannot be transferred here. Older GRF(1-29) studies provide pathway context but do not establish identity or clinical outcomes for a catalog without-DAC lot.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
In five healthy volunteers, GRF1-29 and longer GRF fragments produced GH peaks 15–30 minutes after an intravenous bolus.
Older pathway context; not a matched trial of commercial “CJC-1295 without DAC.”
Read the primary studyThe multi-day half-life reported for CJC-1295 depends on its albumin-binding drug-affinity-complex design.
Keep the two product families, schemas and evidence summaries separate.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 2 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Losa M, et al. Klinische Wochenschrift. 1984. PMID 6240568.
View primary recordRivier J, et al. Annals of the New York Academy of Sciences. 1988. PMID 3133968.
View primary recordThird-party publications selected for direct relevance.
Losa M, et al. Klin Wochenschr. 1984. PMID 6240568.
Rivier J, et al. Ann N Y Acad Sci. 1988. PMID 3133968.
Concise answers for researchers comparing identity, evidence and catalog variants.
No. The DAC form has an albumin-reactive modification that changes persistence and evidence relevance.
The complete sequence, substitutions, terminal form, molecular mass and lot-specific analytical results.
Family-level identifiers organize the catalog, while the applicable product specification and lot-specific COA control the supplied form, identity and release results.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
The best-known CJC-1295 human studies tested an albumin-binding DAC construct. A product labeled “CJC-1295 without DAC” lacks that defining feature, so quoting the 5.8–8.1…
Updated August 28, 2026
The phrase “without DAC” tells the reader what is absent, but it may not fully tell them what is present. Reproducible research requires an…
Updated August 28, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: CND2 · 2 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
